Mounjaro's medical name is tirzepatide — here's what that tells you

What the name 'tirzepatide' is actually telling you

Pharmaceutical naming follows a strict international convention. The generic name, formally called the International Non-Proprietary Name (INN), describes the molecule rather than the brand. Tirzepatide is Mounjaro's INN, assigned by the World Health Organization before Eli Lilly gave the product its commercial title. The suffix -tide signals a synthetic peptide; the tirze- root encodes the dual-receptor mechanism that sets it apart from older GLP-1 drugs. Every peer-reviewed trial (including SURMOUNT-1, which enrolled over 2,500 adults with obesity) was published under the generic name, which is why a web search for the medical name often turns up clinical papers rather than the manufacturer's website.

In practice, Mounjaro and tirzepatide are exactly the same thing. Your prescription, your GP record and your pharmacist's dispensing system will carry the INN. Patients sometimes worry when they see a different-looking word on their documentation, but a Mounjaro prescription labelled 'tirzepatide' is entirely correct. You can read the full prescribing detail on the Mounjaro SmPC on the eMC, where tirzepatide is the named compound throughout.

One thing worth understanding: the brand name is UK-specific. In the United States, Eli Lilly sells tirzepatide for weight management under a different name entirely. What the molecule is (a dual GIP and GLP-1 receptor agonist) is the same regardless of the packaging on the shelf.

What the dual-receptor mechanism means in plain terms

Most GLP-1 medicines activate a single receptor involved in appetite signalling and blood-sugar regulation. Tirzepatide activates two: the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Both are gut-hormone pathways that influence how full you feel, how quickly your stomach empties and how your body handles glucose after eating. No other weight-management medicine currently licensed in the UK works on both pathways at once.

This dual action is the structural reason SURMOUNT-1 reported average body-weight reductions of around 20–21% at the 15 mg dose over 72 weeks, figures that made the trial, published in the New England Journal of Medicine, significant in the weight-medicine field. If you are weighing up how tirzepatide compares with semaglutide, the mechanism difference is one of the key factors; our comparison of weight-loss injection options covers this in more depth.

None of that, however, determines whether tirzepatide is right for you as an individual. The prescriber's job is to look at your full medical picture (existing conditions, current medicines, BMI and circumstances) not just the trial averages. The drug's name tells you what it does biochemically; it cannot tell you what your clinical assessment will conclude.

Does knowing the generic name affect how you access treatment?

For most patients the honest answer is: not directly. You cannot self-prescribe tirzepatide any more than you can self-prescribe Mounjaro. The medicine is a POM under UK law regardless of which name appears on the box. What the generic name does affect is research. If you're reading clinical literature before making a decision (which is a sensible thing to do) searching 'tirzepatide' will surface the SURMOUNT trials, NICE's appraisal (TA1026, published December 2024), and the BNF monograph for tirzepatide, all of which use the INN.

It also matters when transferring between providers or reviewing a repeat prescription. Knowing that 'tirzepatide 10 mg solution for injection' on your clinical record refers to the Mounjaro 10 mg KwikPen prevents unnecessary confusion. Some patients transfer to a regulated online pharmacy mid-course; if that's your situation, the guide to Mounjaro as a medication walks through how transfer works in practice.

The route to a private prescription for tirzepatide runs through a regulated pharmacy with a GPhC-registered Independent Prescriber on the clinical team. You can verify any UK online pharmacy on the GPhC register before handing over your details. That step takes about 30 seconds and is, genuinely, worth doing. At nume, a named prescriber (not software) reviews each consultation before anything is approved or dispatched.

Tirzepatide, Mounjaro and the names you might see elsewhere

The brand Mounjaro is Eli Lilly's registered trademark in the UK. The molecule tirzepatide is what NICE evaluated, what the MHRA licensed and what your prescriber prescribes. Some people also encounter the term 'dual GIP/GLP-1 receptor agonist' in medical writing, that is a description of the drug class, not a brand or INN, though it maps precisely onto tirzepatide's mechanism.

If you have come across a different name entirely (one used in the US market) that product is not available from UK pharmacies and does not appear on the UK licence. Pages on our site that cover tirzepatide in detail or the Mounjaro treatment overview use both names interchangeably where the context warrants it, because they refer to the same compound. There is no clinical or practical difference between a page titled with the brand and one titled with the INN, the information underneath should be consistent. For a closer look at the naming conventions specifically, see our companion page on the tirzepatide chemical name.

If you're at the stage of thinking about whether tirzepatide might be appropriate for your situation (rather than just curious about what the name means) the natural next step is a clinical conversation, and our Mounjaro medical page is a good place to review what that process involves before you begin. Our free consultation puts your answers in front of a prescriber the same day, and you'll get a clear decision rather than a waiting list. Check your eligibility and start your free consultation when you're ready.